Costs of introducing pneumococcal, rotavirus and a second dose of measles vaccine into the Zambian routine immunisation schedule: Are expansions sustainable?

PI: Ulla Griffiths
Funding: Bill and Melinda Gates Foundation through Center for Infectious Disease Research in Zambia (CIDRZ)

Introductions of new vaccines in low-income countries have accelerated since the GAVI Alliance was established in 2000. In this study the economic costs and the sustainability of introducing pneumococcal conjugate vaccine (PCV), rotavirus vaccine and a second dose of measles vaccine into routine immunisation services in Zambia are being estimated. Data on vaccine supplies, cold storage expansion, training and social mobilisation and costs were collected during 2013 from document reviews and by gathering information from the Government and international partner organisations. This was complemented by results of an Expanded Programme on Immunisation Costing study conducted in Zambia during 2012-13, which included estimates of human resources costs per dose of vaccine. Incremental costs per child fully vaccinated with three doses of pentavalent vaccine (penta3 child) were calculated. A fiscal space analysis is being conducted to assess sustainability after graduation from GAVI. The study is undertaken in collaboration with Strategic Development Consulting (SDC), South Africa, Center for Infectious Disease Research in Zambia (CIDRZ), Ministry of Community Development, Mother and Child Health, Zambia and the World Bank, Zambia Country Office.